Stock comparison
Genmab A/S
Merit Medical Systems
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
MMSI
Merit Medical Systems
Market cap
$3.83B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | MMSI | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 58D | GMAB |
| Benjamin Graham | 64C | 73B | MMSI |
| Philip Fisher | 48D | 59C | MMSI |
| Peter Lynch | 25F | 52C | MMSI |
| Joel Greenblatt | 76B | 39D | GMAB |
| Charlie Munger | 68C | 45D | GMAB |
| Terry Smith | 71C | 49D | GMAB |
Side-by-side metrics
| Metric | GMAB | MMSI |
|---|---|---|
| Market cap | $16.5B | $3.83B |
| P/E (TTM) | 6.2x | 27.0x |
| EV/EBIT | 12.0x | 22.2x |
| ROIC (TTM) | 43.78% | 5.56% |
| Gross margin | 93.88% | 48.65% |
| Net margin | 18.23% | 9.03% |
| Revenue CAGR 5y | -18.45% | 8.96% |
| EPS CAGR 5y | -23.48% | 26.03% |
| Debt / Equity | 0.1x | 0.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs 5.56%+87%
- Debt / Equity0.1xvs 0.5x+85%
- P/E (TTM)6.2xvs 27.0x+77%
- Market cap$16.5Bvs $3.83B+77%
MMSI leads on
- EPS CAGR 5y26.03%vs -23.48%+190%
- Revenue CAGR 5y8.96%vs -18.45%+149%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.